New Zealand markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
47.80-0.12 (-0.25%)
At close: 04:00PM EST
48.21 +0.41 (+0.86%)
Pre-market: 07:28AM EST
Full screen
Trade prices are not sourced from all markets
Previous close47.92
Open47.89
Bid0.00 x 800
Ask0.00 x 800
Day's range47.72 - 48.23
52-week range42.63 - 57.82
Volume1,986,059
Avg. volume1,760,959
Market cap119.362B
Beta (5Y monthly)0.44
PE ratio (TTM)20.52
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.90 (3.98%)
Ex-dividend date30 May 2023
1y target estN/A
  • GlobeNewswire

    Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

    Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation Priority Review granted based on positive results from two Phase 3 trialsIf approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more than a decadeRegulatory submissions are also under review in China and Europe Paris and Tarrytown, N.Y. February 23, 2024. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the s

  • GlobeNewswire

    Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

    Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors Paris, February 22, 2024. At its meeting on February 22, 2024, Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2024, the renewal of the terms of office of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directo

  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares - January 2024

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi